uniQure (NASDAQ:QURE – Get Free Report) shares saw strong trading volume on Wednesday after The Goldman Sachs Group raised ...

Qure (NASDAQ:QURE – Get Free Report)‘s stock had its “buy” rating reaffirmed by Guggenheim in a report released on ...

Raymond James and Cantor both released bullish notes on uniQure (QURE) Tuesday following an update on the company's ...

Qure (NASDAQ:QURE – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research note issued to investors on Wednesday. Other research analysts have also ...

Verition Fund Management LLC lowered its position in uniQure (NASDAQ:QURE – Free Report) by 77.9% during the third quarter, ...

Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...

UniQure (QURE) stock shot up 90% on news the company had reached an agreement with the FDA on an accelerated approval pathway ...

Walleye Capital LLC purchased a new stake in uniQure (NASDAQ:QURE – Free Report) in the third quarter, according to the ...

Dutch gene therapy company uniQure saw its shares rocket 86% to $13.57 today, after it reached agreement with the US Food and ...

The FDA will allow uniQure NV to seek accelerated approval for its Huntington’s disease gene therapy more than doubled the ...

Qure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.

Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...